Discordant Response to Nivolumab Plus Ipilimumab and Identification of

Olivia Wilkins, Adedamola Omogbehin, Peter J Bergquist, Chul Kim, Stephen V Liu, Joshua E Reuss

Abstract readCase Reports

In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Olivia WilkinsLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.

Adedamola OmogbehinDepartment of Radiation Oncology, MedStar Washington Hospital Center, Washington, DC.

Peter J BergquistDepartment of Radiology, Georgetown University, Washington, DC.

Chul KimLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.

Stephen V LiuLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.

Joshua E ReussLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic advancement for malignant pleural mesothelioma (MPM) has been limited. Combination immunotherapy with nivolumab plus ipilimumab is a frontline treatment option for advanced MPM that is typically deployed for patients with sarcomatoid or biphasic MPM. Here, we present a case of biphasic MPM that exhibited a unique response pattern to first-line treatment with nivolumab plus ipilimumab, with brisk response in pleural and mediastinal sites of disease, but rapid progression in osseous/soft tissue sites of disease complicated by pathologic spinal cord compression. Pathologic findings from bony metastasis at progression found pure epithelioid histology without any evidence of sarcomatoid differentiation. Next-generation sequencing of this specimen revealed a

Indexed as

BRAF V600ECase reportDabrafenibMalignant pleural mesotheliomaTrametinib

Identifiers

PMID40225956

DOI10.1016/j.jtocrr.2025.100820

PMCPMC11986214

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.